Key Takeaways
- Steady quarter, pipeline building: Generics delivered stable volumes despite pricing pressure, while Custom Synthesis advanced multiple projects toward commercial volumes over the next year, and the peptide segment supported customer programs across all clinical phases.
- GLP-1 infrastructure taking shape: The pilot plant is complete, a dedicated peptide building block with large-scale SPPS reactors is constructed, and validations are underway, though management declined to disclose capacity specifics.
- Three dedicated capex projects on track for 2027: All three molecules disclosed to SEBI are expected to begin commercialization by calendar year-end 2027, subject to customer approvals and regulatory timelines.
- Margins benefited from mix, not just cost: Gross margin improvement came from a richer Custom Synthesis mix in the nine-month period and quarter-on-quarter product lumpiness, with a ₹74 crore exceptional charge for revised employee benefit obligations under new labour codes.
- What to watch next quarter: Whether the CS projects completing validation translate into firm commercial volume commitments, any signal on China export rebate fallout for basic chemical pricing, and progress on Kakinada Phase 2 evaluation.
Custom Synthesis Pipeline & Commercialization
- Multiple projects nearing commercial stage: Several projects are progressing through development and validation, with a few moving closer to commercial volumes over the next 1 year; validations have been completed or are ongoing, and the company is waiting for customer regulatory approvals before volumes are discussed.
- Broad timeline, product-dependent: Management indicated second half FY27 as a broad commercialization window, but stressed that timing depends product-to-product: some validations completed this quarter, some ongoing, and some planned for next month, after which data goes to the customer for submission.
- Existing infrastructure ready: Most production blocks are multipurpose and can quickly absorb commercial volumes in existing capacities; specific equipment for specific processes would be procured as needed.
- Three dedicated capex projects: All three molecules declared to SEBI are expected to start commercialization by 2027, post customer approvals; commercial volumes should begin moving in Q3/Q4 of calendar year 2027 assuming regulatory approvals arrive on time.
- CDA constraints limit disclosure: Management declined to specify what proportion of commercializing molecules are already approved for innovators versus first-time approvals, citing Confidential Disclosure Agreements, and would only describe work across three segments: Phase II/III innovators, secondary source, and late life-cycle support.
Dr. Kiran S. Divi: "By the end -- by 2027, we should start seeing commercialization post our customers, they start approving the product."
Peptide Business Build-Out
- Deep legacy, renewed demand: Divi's was heavily involved in protected amino acids from 2000-2006 for an MNC; after the project phased out, customers requested restart in the last 5 years, and production has scaled from a few hundred kilos for validations to multiple tens of tonnes for individual amino acids.
- Infrastructure milestones: The GLP-1 pilot plant is complete, and one commercial building with several large-scale SPPS reactors designed to customer requirements is finished with validations ongoing. A dedicated building block for peptides including various SPPS reactors has also been constructed.
- Scope beyond GLP-1s: The company works across other peptide categories including Phase I and Phase II programs; psoriasis is noted as a big market opportunity.
- Vertically integrated supply chain: Divi's produces protected amino acids that it supplies to fragment manufacturers, and also uses its own protected amino acids for its own fragments supplied to innovators; as commercial volumes increase, internal intake of its own protected amino acids will also rise.
- Capacity disclosure off-limits: Management declined to speak about GLP-1 capacity created, stating only that validations are moving forward now that pilot work is done.
Dr. Kiran S. Divi: "I'm not at the liberty to speak about capacity created, but the validations are going on as we speak right now because pilot work is done, now it's moving towards validations."
Generics & Operating Environment
- Volume growth, value lag: Generics volume has had good growth but pricing pressures continue, so value-wise the segment does not reflect the volume growth; the pricing environment remains competitive with healthy volume traction in certain emerging and focused products.
- Backward integration advantage: Strong backward integration, process efficiencies, and the ability to develop and deliver across regions supported stable generics performance; Unit 3 at Kakinada is playing an important role in that strategy, with operational blocks used for starting materials and intermediates.
- Raw material stability, China overhang: Raw material prices and availability were broadly stable during the quarter, supported by a diversified vendor base and backward integration. The company is watching China's withdrawal of export tax rebates on certain products, which may result in selective pricing pressures over time, though the impact is seen more on basic chemicals than on intermediates and final APIs where some exemptions exist.
- Procurement diversification: Divi's has been diversifying procurement away from China for many years, increasing its domestic supplier base to 78% of procurement to ensure made-in-India and just-in-time material supply.
- Logistics and freight: Manageable during the quarter with freight rates largely stable.
Margins & Financials
- Gross margin drivers: Improvement was driven mainly by product mix, with Custom Synthesis improving in the nine-month period versus the previous nine months; quarter-on-quarter improvement also reflected product lumpiness, with some products carrying higher margins and some lower.
- Exceptional item: A ₹74 crore charge was taken relating to employee benefit obligations, triggered by the Government of India notifying four labour codes on November 21, 2025, which revised the definition of wages.
- Hedging stance: The company is currently not hedging and is evaluating the position based on the overall market scenario.
- Asset turnover ambition: Management aims to return the gross asset turnover ratio to its historical high of 1.5 to 1.8 over the next 4-5 years, based on revenue visibility from dedicated capex and the CS pipeline.
Nilima Prasad Divi: "We are not hedging. We are evaluating at this point based on the overall scenario in the market."
Technology & Process Innovation
- New technology platforms: The company is expanding its technology platforms with increased use of process automation and multiple new chemistry platforms, scaling into commercial manufacturing to improve process safety, minimize heat buildup, and strengthen production.
- Emerging techniques: Divi's is looking at mechanochemistry and electrochemistry for operational efficiencies, and automation for GMP requirements, especially for complex operations like azide chemistry.
- Resin development: The company is working on resins but this remains at the R&D phase.
- Manufacturing flexibility: On peptide manufacturing, management emphasized that the company will manufacture based on the technology the customer provides, since it is producing fragments for innovators, not generics.
Dr. Kiran S. Divi: "It's not complicated, okay, we will manufacture it based on the technology he has provided because they're only manufacturing fragments for innovators. They are not in the generic business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Dedicated capex commercialization | All 3 molecules declared to SEBI begin commercial volumes, subject to regulatory approvals | Q3/Q4 calendar year 2027 |
| CS project commercial volumes | Multiple projects moving closer to commercial volumes; validations completed or ongoing | Next 1 year (broadly H2 FY27, product-dependent) |
| Double-digit growth trajectory | No disruption foreseen; equilibrium maintained as products move through lifecycle | Ongoing |
| Gross asset turnover ratio | Return to historical high of 1.5 to 1.8 | Next 4-5 years |
| Raw material environment | Expected to remain broadly stable in pricing and availability | Next 6 months |
| Nutraceuticals momentum | Healthy performance expected to carry forward | Ongoing |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated total income | ₹2,692 cr, compared to ₹2,401 cr in Q3 FY25 |
| Profit before exceptional item and tax | ₹854 cr, compared to ₹726 cr in Q3 FY25 |
| Exceptional item (labour codes impact) | ₹74 cr, one-time incremental employee benefit obligation |
| Profit before tax (after exceptional item) | ₹780 cr |
| Profit after tax | ₹583 cr, broadly in line with ₹589 cr in Q3 FY25 |
| Material consumption | 36.3% of sales revenue, vs 39.8% in Q3 FY25 |
| Product mix (Generics / CS) | 43% / 57% |
| Export share | ~89% of total sales revenue; Europe and US 73% of export sales |
| Nutraceutical segment revenue | ₹214 cr |
| Foreign exchange gain | ₹19 cr, included in other income |
| 9-month constant currency growth | 8.6% |
| Capacity utilization | 70% to 80%, varying by month and shipment timing |
| Assets capitalized (quarter) | ₹313 cr |
| Capital work in progress | ₹2,394 cr as of Dec 31, 2025 |
| Cash and cash equivalents | ₹3,686 cr as of Dec 31, 2025 |
| Domestic supplier base | 78% of procurement quantity |